Future cardiology最新文献_第5页

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction. 共病性精神障碍对ST段抬高型心肌梗死后住院死亡率和并发症的影响

IF 1.1

Future cardiology Pub Date : 2026-07-01 Epub Date: 2026-06-22 DOI: 10.1080/14796678.2026.2686697

Akash Gopal, Prit Patel, Abdul Rasheed Bahar, George Kidess, Jawad Basit, M Chadi Alraies

{"title":"Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.","authors":"Akash Gopal, Prit Patel, Abdul Rasheed Bahar, George Kidess, Jawad Basit, M Chadi Alraies","doi":"10.1080/14796678.2026.2686697","DOIUrl":"10.1080/14796678.2026.2686697","url":null,"abstract":"Background: Psychiatric comorbidities are common among patients with ST-segment elevation myocardial infarction (STEMI) and may be associated with in-hospital outcomes, which may differ among sexes.Methods: Using the National Inpatient Sample, an administrative claims database, we identified adults hospitalized with STEMI and psychiatric comorbidities and performed a retrospective cross-sectional observational study. Multivariable logistic regression and propensity-score matching were applied; outcomes were assessed between females and males with subgroup analyses for individual psychiatric conditions.Results: Of 145,830 patients, 45.51% were female. Female sex was associated with higher odds of in-hospital mortality (aOR 1.13, 95% CI: 1.01-1.26, p = 0.031) and pulmonary embolism (aOR 1.54, CI: 1.05-2.26, p = 0.027), and lower odds of cardiogenic shock (aOR 0.85, 95% CI: 0.79-0.92, p < 0.001). Female sex was also associated with lower odds of acute heart failure, acute kidney injury, cardiac arrhythmias, and device use (p < 0.05). Directional associations persisted after propensity-matching. Subgroup analyses corroborated trends and revealed female post-traumatic stress disorder patients demonstrated higher odds of in-hospital mortality (aOR 2.40, 95% CI 1.37-4.22, p = 0.002).Conclusion: Among patients with STEMI and psychiatric disorders, female sex was associated with higher odds of in-hospital mortality and lower odds of several adverse complications. Psychiatric comorbidities are heterogeneous, however, and findings vary.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"695-705"},"PeriodicalIF":1.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic cardiac migration of perfluorocarbon liquid following unsuccessful endoresection of choroidal melanoma: a case report. 脉络膜黑色素瘤内切不成功后全氟碳液体的全身心脏迁移一例报告。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-05-27 DOI: 10.1080/14796678.2026.2680047

Tomislav Jukić, Luka Ivić, Nenad Vukojević, Tomislav Bulum, Martina Tomić

{"title":"Systemic cardiac migration of perfluorocarbon liquid following unsuccessful endoresection of choroidal melanoma: a case report.","authors":"Tomislav Jukić, Luka Ivić, Nenad Vukojević, Tomislav Bulum, Martina Tomić","doi":"10.1080/14796678.2026.2680047","DOIUrl":"10.1080/14796678.2026.2680047","url":null,"abstract":"Choroidal melanoma (CM) is the most common intraocular malignant tumor in adults, with a high rate of metastasis and mortality. This study reports a case of systemic cardiac migration of perfluorocarbon liquid (PFCL) following an unsuccessful endoresection of CM. A 61-year-old woman underwent gamma knife radiosurgery and pars plana vitrectomy endoresection for CM in her left eye. The procedure was complicated by intraocular bleeding, leading to incomplete tumor removal, with the eye filled with PFCL and blood before closure. The patient refused further surgery and later developed secondary glaucoma. Nearly three years later, during an acute increase in intraocular pressure reaching 50 mmHg, she experienced severe respiratory insufficiency requiring intubation and veno-arterial extracorporeal membrane oxygenation (V-A ECMO). Echocardiography showed a severely dilated right ventricle and echogenic material in the left atrium and ventricle, while acute coronary syndrome and pulmonary embolism were ruled out. The patient's respiratory status stabilized, and intracardiac echogenic material was observed during the first three days of V-A ECMO but was absent afterward. In summary, cardiac PFCL migration can occur after endoresection for choroidal melanoma; therefore, specific precautions should be taken to prevent and promptly detect this complication.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"575-582"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrosternal extravascular implantable cardioverter-defibrillators: a systematic review of implant characteristics, defibrillation testing, and acute safety. 胸骨后血管外植入式心律转复除颤器：植入式特性、除颤试验和急性安全性的系统综述。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-06-03 DOI: 10.1080/14796678.2026.2676272

George H Crossley, Jamie Kowal, Allison Siehr, Thomas R Holmes, Alberto Aimo

{"title":"Retrosternal extravascular implantable cardioverter-defibrillators: a systematic review of implant characteristics, defibrillation testing, and acute safety.","authors":"George H Crossley, Jamie Kowal, Allison Siehr, Thomas R Holmes, Alberto Aimo","doi":"10.1080/14796678.2026.2676272","DOIUrl":"10.1080/14796678.2026.2676272","url":null,"abstract":"Introduction: Implantable cardioverter-defibrillators (ICD) terminate potentially deadly ventricular arrhythmias in at-risk patients. Retrosternal extravascular ICDs (EV-ICD) place a lead in the mediastinal space to provide both shock and antitachycardia pacing therapy without the need for venous access. A systematic review was performed to assess acute outcomes in patients implanted with a retrosternal EV-ICD.Methods: A query of EMBASE and MEDLINE databases was performed to identify unique retrosternal EV-ICD cohort studies published between JAN-1-2020 and JAN-31-2026. Two known retrosternal EV-ICDs were included, the market-approved Medtronic substernal EV-ICD system and investigational AtaCor intercostal EV-ICD lead. Procedure and defibrillation testing details and acute safety data were collected.Results: Fourteen articles (n = 806 patients) met criteria for inclusion. Lead placement success was 99.6% and 97.3% while defibrillation testing success was 98.5% and 97.2% for the substernal EV-ICD system and intercostal EV-ICD lead, respectively. Periprocedural complications were manageable with a rate of 1.5% (n = 11/731) for the substernal EV-ICD system and 8.2% (n = 6/73) for the intercostal EV-ICD lead.Conclusions: The available evidence suggests that periprocedural outcomes and acute safety of retrosternal EV-ICD systems, particularly the substernal EV-ICD system, is an effective and safe strategy that provide potentially lifesaving therapy while preserving the vasculature.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420261328371.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"659-671"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Best practices in specialized hypertrophic cardiomyopathy centers in the United States: a survey of cardiologists, nurses, pharmacists, patients, and patient advocates. 美国专业肥厚性心肌病中心的最佳实践：对心脏病专家、护士、药剂师、患者和患者倡导者的调查。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-06-11 DOI: 10.1080/14796678.2026.2680049

Martin Maron, Barbara Steeves, Andrew Wang

{"title":"Best practices in specialized hypertrophic cardiomyopathy centers in the United States: a survey of cardiologists, nurses, pharmacists, patients, and patient advocates.","authors":"Martin Maron, Barbara Steeves, Andrew Wang","doi":"10.1080/14796678.2026.2680049","DOIUrl":"10.1080/14796678.2026.2680049","url":null,"abstract":"Background: This survey gained insights into best practices and challenges at specialized hypertrophic cardiomyopathy (HCM) centers in the US to inform improvements in clinical practice and patient care, and support those without proximity to specialized centers.Methods: We conducted a qualitative survey of eligible health care providers employed at comprehensive HCM centers. Institutions offered septal reduction therapies, implantable cardioverter defibrillator implants, and heart transplants. Patients and a patient advocacy group were also interviewed.Results: A high degree of consistency in care team structure and standardization of processes for HCM diagnosis, including imaging and management, was observed. Patient and care team education on treatments, including cardiac myosin inhibitors, was critical for informed decision-making and efficiency. Further primary cardiology education could include HCM detection and management, including assessing sudden death risk. Community setting education was recognized as important for continuity of care. Major challenges included funding, and lack of dedicated HCM teams including administrative staff, ancillary specialists, and experienced sonographers.Conclusions: Diagnostic testing expertise and understanding of optimal processes, including different treatment options, are important to improve quality of care and outcomes. Select management considerations and best practices from comprehensive HCM centers may be adoptable by primary cardiology centers and providers.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"583-592"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: current evidence, limitations, and future directions. 超声辅助导管溶栓治疗肺栓塞：目前的证据、局限性和未来的方向。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-06-15 DOI: 10.1080/14796678.2026.2680046

Bana Hadid, Daniel J Snyder, Robert S Zilinyi, Sanjum S Sethi, Sahil A Parikh

{"title":"Ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: current evidence, limitations, and future directions.","authors":"Bana Hadid, Daniel J Snyder, Robert S Zilinyi, Sanjum S Sethi, Sahil A Parikh","doi":"10.1080/14796678.2026.2680046","DOIUrl":"10.1080/14796678.2026.2680046","url":null,"abstract":"Pulmonary embolism (PE) is the third leading cause of cardiovascular death globally and continues to carry high rates of morbdity and mortality despite advances in therapy. While risk stratification helps guide treatment for both low- and high-risk patients, optimal management of intermediate-risk PE remains unclear. Although contemporary AHA/ACC guidelines introduce more granular clinical categories to better define risk and guide treatment selection within this heterogeneous population, uncertainty persists. Systemic fibrinolysis poses bleeding risks, whereas anticoagulation alone may not be sufficient to prevent clinical deterioration. Catheter-based approaches, such as ultrasound-assisted catheter-directed thrombolysis (UACDT), have therefore emerged as potential options that deliver lower-dose fibrinolytics directly into the pulmonary arteries. However, much of the existing literature combines UACDT with other catheter-based interventions, making it difficult to isolate its specific contribution. The data are also heterogeneous, limiting cross-study comparisons. This review summarizes the current evidence, influential clinical trials, and ongoing studies on UACDT, with a focus on its therapeutic potential, safety considerations, limitations, and evolving role in the management of intermediate-risk PE. A literature search was conducted using PubMed, Embase, and ClinicalTrials.gov from inception through early 2026, with supplementary searches performed using Google Scholar.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"633-657"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148250760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of pullback pressure gradient in guiding coronary artery disease management. 回拉压力梯度在指导冠状动脉疾病治疗中的作用。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-05-24 DOI: 10.1080/14796678.2026.2654616

Kazumasa Ikeda, Anthony Kechichian, Ganeev Malhotra, Frederic Bouisset, Koshiro Sakai, Mitsuaki Matsumura, Takuya Mizukami, Carlos Collet

引用次数: 0

Combination pitavastatin-ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis. 匹伐他汀-依折替米联合治疗高胆固醇血症和混合性血脂异常：一项系统综述和荟萃分析。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-05-25 DOI: 10.1080/14796678.2026.2676249

Muhammad Sharjeel Abbas, Asia Batool, Muhammad Hussain, Muhammad Hassan, Asharib Sohaib, Taha Ahmed, Maryam Athar, Saifullah Khan, Warisha Kanwal, Makhzan Ali Akbar, Abdul Hannan

{"title":"Combination pitavastatin-ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis.","authors":"Muhammad Sharjeel Abbas, Asia Batool, Muhammad Hussain, Muhammad Hassan, Asharib Sohaib, Taha Ahmed, Maryam Athar, Saifullah Khan, Warisha Kanwal, Makhzan Ali Akbar, Abdul Hannan","doi":"10.1080/14796678.2026.2676249","DOIUrl":"10.1080/14796678.2026.2676249","url":null,"abstract":"Background: Dyslipidemia is a prevalent and major contributor to atherosclerotic cardiovascular disease; however, many patients do not achieve the recommended low-density lipoprotein cholesterol goals with statin monotherapy. Thus, the efficacy of complementary therapeutic options must be investigated.Objective: To evaluate the lipid-lowering efficacy and safety of pitavastatin combined with ezetimibe versus pitavastatin monotherapy in adults with hypercholesterolemia or mixed dyslipidemia.Methods: A systematic search of PubMed, Embase, Cochrane Library, and Scopus (November 2025) identified randomized controlled trials that compared pitavastatin 2 mg or 4 mg plus ezetimibe 10 mg with pitavastatin 2 mg alone. The protocol for this systematic review and meta-analysis was prospectively registered in PROSPERO. A random-effects meta-analysis was used to pool lipid and safety outcomes. The risk of bias was assessed using RoB 2, and the certainty of evidence was graded using the GRADE tool.Results: Non-high-density lipoprotein cholesterol, total cholesterol, and Apolipoprotein B. Changes in high-density lipoprotein cholesterol and triglyceride levels were modest but more pronounced at week 12.Conclusion: Combination therapy offers an apparent enhancement in lipid lowering and may serve as an effective supplementary option for patients who require more intensive low-density lipoprotein cholesterol management. However, the limited evidence warrants further research.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251233057.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"607-619"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the efficacy and safety of ethacizine in the management of premature atrial and ventricular contractions - a prospective study (ETHAPRO). 评价乙昔嗪治疗心房和心室早搏的有效性和安全性-一项前瞻性研究（ETHAPRO）。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-06-08 DOI: 10.1080/14796678.2026.2686702

Nika Kuridze, Kakhaber Etsadashvili, Eteri Minadze

{"title":"Evaluation of the efficacy and safety of ethacizine in the management of premature atrial and ventricular contractions - a prospective study (ETHAPRO).","authors":"Nika Kuridze, Kakhaber Etsadashvili, Eteri Minadze","doi":"10.1080/14796678.2026.2686702","DOIUrl":"10.1080/14796678.2026.2686702","url":null,"abstract":"Background: Premature atrial contractions (PACs) and premature ventricular contractions (PVCs) are among the most frequently observed arrhythmias in clinical practice. They represent early depolarizations originating from the atria or ventricles, respectively, and are often detected in both healthy individuals and patients with cardiovascular disease.Patients and methods: In the ETHAPRO study, 98 patients (58 males, 40 females; mean age 45 years) with either PACs (n = 46) or PVCs (n = 52) were enrolled. All participants had an ectopic burden of >1000 premature beats per 24 h despite prior antiarrhythmic therapy. Patients were treated with ethacizine (50 mg b.i.d.) and were followed at 30-45 days (short-term) and 150-210 days (long-term). The endpoints were a reduction in ectopic burden to ≤1000 beats per 24 h, symptomatic improvement and safety assessments.Results and conclusions: Ethacizine treatment led to significant reductions in PACs (88.9%/ 91.7%; p < 0.001) and PVCs (82.8%/ 84.8%; p < 0.001). A total of 89.0% of PAC patients and 86.0% of PVC patients achieved the predefined target. Symptomatic improvement was reported in 91.0% of patients with PAC and 85.0% of patients with PVC. Ethacizine demonstrated robust and sustained antiarrhythmic efficacy with a favorable safety profile in patients with refractory PACs and PVCs.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"593-599"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carotid artery stenosis: a guide for clinicians. 颈动脉狭窄：临床医生指南。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2025-07-22 DOI: 10.1080/14796678.2025.2530909

Kamran Namjouyan, Jonathan A Tangsrivimol, Affan Rizwan, Iqra Riaz, Johao Escobar, Muzamil Khawaja, Hafeez Hassan Virk, Mahboob Alam, Alan Dardik, Chayakrit Krittanawong

引用次数: 0

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency. 多学科方法应用羧基麦芽糖铁治疗心力衰竭伴缺铁患者静脉补铁。

IF 1.1

Future cardiology Pub Date : 2026-06-01 Epub Date: 2026-06-03 DOI: 10.1080/14796678.2026.2683489

Marat Fudim, Francesco Ferrante, Cassandra M Vorgang, Carolyn M Rosner, Robert J Mentz

{"title":"Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.","authors":"Marat Fudim, Francesco Ferrante, Cassandra M Vorgang, Carolyn M Rosner, Robert J Mentz","doi":"10.1080/14796678.2026.2683489","DOIUrl":"10.1080/14796678.2026.2683489","url":null,"abstract":"Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF). Treatment with intravenous (IV) iron is recommended by the ACC/AHA/HFSA and ESC guidelines to improve HF symptoms, exercise capacity, and quality of life, and to reduce the risk of hospitalization. Ferric carboxymaltose (FCM) is indicated for ID in adults with HF (NYHA class II/III) to improve exercise capacity. There are challenges in ensuring that eligible patients with HF and ID achieve iron repletion and associated optimal outcomes in routine practice. These challenges include inpatient formulary restrictions which only allow for low-dose IV irons and care transitions when the course of IV iron treatment spans the inpatient and outpatient setting. Despite the ease of administration as a single rapid infusion of up to 1000 mg of iron, inpatient and outpatient formularies do not always include FCM. This guide shares a general workflow used at university-based and private hospital systems, to facilitate routine iron assessment and IV iron repletion in a typical HF care pathway. Perspectives from the cardiologist, nurse, advanced practice provider (APP), and pharmacist roles provide a comprehensive view and emphasize the importance of a multidisciplinary, collaborative approach to optimize outcomes for patients with HF and ID.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"567-574"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0